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glioma models can lead to deceptive results when such char-
acteristics are not properly taken into account.
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Introduction
Clinicopathology of gliomas
Glioma is a rare cancer (6 diagnoses per 100,000 people 
annually) of the central nervous system (CNS) originating 
Abstract In theory, in vitro and in vivo models for human 
gliomas have great potential to not only enhance our under-
standing of glioma biology, but also to facilitate the devel-
opment of novel treatment strategies for these tumors. For 
reliable prediction and validation of the effects of different 
therapeutic modalities, however, glioma models need to com-
ply with specific and more strict demands than other models 
of cancer, and these demands are directly related to the com-
bination of genetic aberrations and the specific brain micro-
environment gliomas grow in. This review starts with a brief 
introduction on the pathological and molecular characteris-
tics of gliomas, followed by an overview of the models that 
have been used in the last decades in glioma research. Next, 
we will discuss how these models may play a role in better 
understanding glioma development and especially in how 
they can aid in the design and optimization of novel therapies. 
The strengths and weaknesses of the different models will 
be discussed in light of genotypic, phenotypic and metabolic 
characteristics of human gliomas. The last part of this review 
provides some examples of how therapy experiments using 
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from (precursors of) glial cells [41]. The vast majority is 
characterized by diffuse infiltrative growth into the sur-
rounding CNS parenchyma [29]. Based on the astrocytic, 
respectively, oligodendroglial phenotype of the cancer 
cells these diffuse gliomas are traditionally histopathologi-
cally typed as diffuse astrocytomas, oligodendrogliomas, 
or as mixed gliomas/oligoastrocytomas. However, the lat-
ter diagnosis is disappearing because nowadays molecular 
testing generally provides an unambiguous diagnosis of 
either astrocytic or oligodendroglial tumor (see “Molecu-
lar pathology of gliomas” and [91]). Furthermore, based on 
the presence/absence of marked mitotic activity, necrosis 
and florid microvascular proliferation (MVP) a malignancy 
grade is assigned to diffuse gliomas (World Health Organi-
zation (WHO) grade II–IV) [68, 159].
A shared characteristic of all grades of diffuse glioma 
is their extensive infiltration in the CNS parenchyma along 
white matter tracts and pre-existing blood vessels [29]. 
Surgical cure for diffuse gliomas is not available because 
complete resection cannot be achieved. Without treatment, 
survival of patients with glioblastoma (not only the most 
malignant, but also by far the most frequent glioma) is 
approximately 6–9 months after diagnosis, and even with 
current standard treatment using a combination of surgery 
irradiation and the DNA-alkylating agent temozolomide, 
survival rates remain dramatically poor [137, 138]. The 
limited progress in implementing novel, more effective 
treatment protocols for diffuse glioma sharply contrasts the 
situation of many other cancer types.
The most frequent examples of gliomas with a circum-
scribed rather than diffuse infiltrative growth pattern are 
pilocytic astrocytoma (relatively common in children and 
generally benign/WHO grade I) and different variants of 
ependymoma (occurring in both children and adults and 
with variable aggressiveness corresponding to WHO grade 
I–III) [33, 53, 153].
Molecular pathology of gliomas
Especially during the last decade, multiple studies have 
shed light on the molecular events underlying gliomagen-
esis and on their clinical relevance as diagnostic, prognos-
tic and/or predictive markers. Some of these markers are 
now incorporated in the definitions of particular glioma 
entities in the recently published, revised WHO classifica-
tion [90, 91]. Heterozygous mutations in the gene encoding 
the metabolic enzyme isocitrate dehydrogenase (IDH) are 
seen in 70–80% of grade II and III diffuse gliomas and in 
12% of glioblastomas [108, 163]. These mutations (mostly 
involving cytosolic IDH1, lesser so mitochondrial IDH2) 
have important consequences for the epigenome and cause 
extensive DNA methylation in IDH-mutant diffuse gliomas 
(‘glioma-CpG island methylator phenotype’/G-CIMP) [22, 
104]. In ‘canonical’ oligodendrogliomas, according to the 
recently published WHO classification of CNS tumors, an 
IDH1 or IDH2 mutation co-occurs with complete and com-
bined deletion of chromosome arms 1p and 19q [20, 44, 56, 
105, 164]. This complete 1p/19q codeletion not only consti-
tutes the genetic hallmark of oligodendrogliomas, but also 
an important favorable prognostic and predictive marker. 
Diffuse astrocytic tumors can be IDH mutant or wild type. 
While most IDH mutant astrocytic tumors are at clinical 
presentation WHO grade II or III, they often progress to a 
grade IV lesion (‘secondary glioblastoma’). It was recently 
shown that IDH1-mutated glioblastomas may experience 
loss of heterozygosity, resulting in absence of wild-type 
IDH1 expression [57]. It is not known yet whether and how 
heterozygosity or homozygosity for IDH mutations influ-
ences biological behavior. The vast majority of diffuse glio-
mas presenting as glioblastoma at first diagnosis are IDH 
wild type (‘primary glioblastomas’) [90, 91, 93, 105].
A number of dysregulated pathways are frequently 
operational in diffuse gliomas that may be amenable for 
pharmacologic intervention (see Fig. 1). Besides frequent 
mutations in the promoter of TERT (telomerase reverse 
transcriptase, involved in maintaining telomere length) 
[44], like in other cancer types three main pathways are fre-
quently (alone or in combination) affected in diffuse glio-
mas/glioblastomas [19]: (I) the phosphoinositide 3-kinase 
(PI3 K)/AKT pathway is often hyperactive as a result of 
activating mutations in or amplifications of genes encod-
ing the upstream receptor tyrosine kinases (RTKs) and/or 
loss of PTEN, a negative regulator of the AKT pathway; 
(II) cell cycle control pathways, e.g. caused by inactivat-
ing mutations in CDKN2A, the gene encoding the MDM2 
inhibitor p14ARF and the cyclin D1-inhibitor p16INK4A, or 
activating mutations in cyclin-dependent kinase (CDK4) 
resulting in uncontrolled progression from the G1 to the 
S-phase of the cell cycle [20, 150]; (III) inactivating muta‑
tions in TP53, prohibiting apoptosis of cells with damaged 
DNA, and resulting in uncontrolled progression of the cell 
cycle, contributing to the gradual accumulation of muta-
tions and increased intratumoral heterogeneity [134].
Of the most frequent non-diffuse gliomas, pilocytic astro-
cytomas are almost always affected by single abnormalities 
of the mitogen-activating protein kinase (MAPK) pathway 
(most frequently by KIAA1549-BRAF fusion, in other cases 
by a BRAF V600E or other mutation affecting this path-
way), indicating that this neoplasm may be a ‘one pathway’ 
disease [33]. Ependymal tumors form a very heterogeneous 
group with regard to not only location, histology and clini-
cal behavior, but also molecular characteristics. Based on 
detailed molecular analyses combined with clinicopathologi-
cal information, nine larger subgroups of ependymoma have 
been identified, some of these carrying a more grim progno-
sis while others behaving relatively indolent [24, 107].
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Intratumoral heterogeneity
Intratumoral heterogeneity was firmly established by genetic 
analysis of multiple biopsies of the same tumor, and even 
on the level of single cells by single-cell RNA-seq analysis 
[74, 109, 133, 142]. Gliomas may contain subpopulations 
of cells carrying mutually exclusive amplifications of onco-
genes EGFR and PDGFRα [130]. In line with these obser-
vations, recurrent gliomas may be genetically markedly dis-
tinct from the tumors from which they originate [71].
A number of the frequently encountered molecu-
lar aberrations in diffuse gliomas are targetable with 
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Fig. 1  Overview of oncogenic pathways in glioma and possibilities 
for pharmacological interventions, relevant for the models described 
in this article. Growth factors bind to RTKs resulting in phosphoryla-
tion and Ras/Raf and PI3 K signaling to Akt and mTOR, thus driving 
cell growth and survival. In a substantial percentage of glioblastomas 
this process is amplified by loss of the counteracting phosphatase 
PTEN. Akt also can phosphorylate MDM2 thereby stabilizing the 
protein. This stabilization causes ubiquitinylation and degradation 
of the tumor suppressor P53, unleashing cyclin D1 complex activity 
and leading to uncontrolled G1-S progression. Loss of control over 
the cell cycle is also induced by CDKN2A mutations as CDKN2A 
products, p14ARF an p16INK4A are important G1-S checkpoint pro-
teins. The PI3 K pathway (activated by phosphorylated growth fac-
tor receptor tyrosine kinases [RTKs] such as EGFR, MET or PDGR) 
may be inhibited by small molecule RTK inhibitors or antibodies 
directed against ligand binding domains of RTKs or the ligands them-
selves, thus prevent ligand-receptor interaction. The cyclin D1 path-
way (resulting in cell cycle progression from G1 to S phase) may be 
inhibited by the CDK4/6 inhibitor palbociclib. Finally, mutations in 
IDH1 or IDH2 result in mutant proteins that catalyze the conversion 
of α-KG to D-2-HG, causing the G-CIMP phenotype and a transcrip-
tional profile leading to gliomagenesis. AGI-5198 specifically inhibits 
IDH1R132H activity by binding to the catalytic site of the protein
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available drugs, examples being inhibitors of RTKs (anti-
bodies and small molecules against among others EGFR, 
MET, PDGFR [112]), inhibitors of CDK4/6 activity (pal-
bociclib [126]) and inhibitors of mutant IDH enzymes 
[124] (see Fig. 1). Despite the wealth of information on 
actionable molecular aberrations and the availability of cor-
responding targeted drugs, apart from bevacizumab (see 
“Angiogenesis inhibition in preclinical glioma models”) 
there has not been any change in approved drug-based 
treatment strategy for these cancers since the introduction 
of temozolomide. An important reason for this frustrating 
notion is the high diversity in genetic aberrations in glioma, 
combined with substantial intratumoral heterogeneity and 
the relatively low incidence of diffuse glioma, precluding 
a
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testing of novel targeted therapies in groups of patients of 
sufficient size. Furthermore, validated predictive biomark-
ers for novel targeted drugs are often lacking. It is thus of 
great importance to have available appropriate preclinical 
glioma models.
Preclinical glioma models
Ideally, a preclinical glioma model meets the follow-
ing requirements; I) Genetic background resembles that 
of (a subset of) human gliomas; II) Genetic, epigenetic 
and phenotypic intratumoral heterogeneity is similar to 
human glioma; III) Model involves an adequate microen-
vironment with regard to immunocompetence, presence of 
blood–brain barrier (BBB) and cell-cell interactions (both 
between tumor cells and with non-neoplastic cells) [106]; 
IV) Model is reproducible and stable over time.
In the following paragraphs we discuss currently 
employed preclinical glioma models, including their rel-
evance with respect to molecular make-up, intratumoral 
heterogeneity, tumor microenvironment, stability and their 
usefulness for testing of novel therapies. Models that will 
be discussed can be categorized as carcinogen-induced 
gliomas in animals, in vitro glioma cell cultures derived 
from human or animal gliomas, glioma xenograft models 
(subcutaneous, orthotopic), and transgenic mouse models 
(Fig. 2). Furthermore, some more ‘exotic’ glioma models 
(e.g., in zebrafish or fruit flies) will be briefly discussed.
Murine models of glioma
Ethyl‑nitrosourea (ENU)‑induced gliomas
A widely used model of diffuse glioma that was introduced 
in the 1970s is based on carcinogen-induced gliomagenesis 
(Fig. 2a). In this model, pregnant animals (mostly rat) are 
injected intravenously with a single dose of N-ethyl-nitro-
sourea (ENU) [127]. The in utero exposure of embryos to 
this DNA-damaging compound induces predominantly 
brain tumors, possibly because DNA-repair mechanisms 
are less active in the brain than in other tissues, resulting 
in higher rates of stable mutations in neural cells. Interest-
ingly, injection of ENU in adult animals does not result in 
brain tumors [129], suggesting that neural precursor cells 
in the developing brain pass through ENU-induced muta-
tions to their progeny, that will cause problems in the event 
they affect oncogenes or tumor suppressor genes. This 
model thus may well represent gliomagenesis in humans 
and allows for the identification of key driver mutations and 
their roles in glioma development in a spatial and temporal 
fashion, especially since the tumors in this model have a 
relatively long latency time (i.e., they become symptomatic 
only months after birth) [17]. Like in a subset of human 
gliomas, TP53 mutations have been identified as key cancer 
drivers in ENU-induced gliomas, resulting in genetic insta-
bility and accumulation of other mutations in oncogenes or 
tumor suppressor genes [98]. Additionally, other mutations 
that are frequently encountered in human gliomas, such 
as amplification of platelet-derived growth factor recep-
tor alpha (PDGFRα), deletion of the cell cycle regulator 
gene CDKN2A, and amplification of the EGFR gene can be 
present in these animal tumors [168], the combination of 
TP53 and PDGFRα mutations being relatively frequent in 
pediatric high grade glioma [78, 111, 116]. A recent study 
demonstrated that a Braf codon 545 mutation (V545E, 
corresponding to the human BRAF V600E mutation) is a 
frequent early event in the development of ENU-induced 
rat gliomas [156]. This mutation can occur in human dif-
fuse gliomas but is more frequently seen in ‘non-diffuse’ 
gliomas.
The ENU-induced model of gliomagenesis gives rise 
to genetically heterogeneous tumors and also involves 
a proper brain microenvironment, including an intact 
immune system and a blood brain barrier (BBB) [119], 
making it to a relevant model. One of the downsides of the 
model is the poorly reproducible character of glioma for-
mation. Consequently, experiments with this model require 
costly and time-consuming studies with high numbers of 
animals. Yet, whereas in the early days in vivo visualization 
Fig. 2  Schematic overview of in vitro and in vivo glioma models. a 
Intravenous injection of ENU into pregnant rat leads to offspring with 
a high chance of spontaneous glioma development. Resulting gliomas 
often carry mutations in oncogenes or tumor suppressor genes that 
are frequently encountered in human gliomas. ENU-induced gliomas 
have been processed to murine glioma cell lines that can be implanted 
as allografts in syngeneic animals. b GEMMs. Shown are examples 
of compound flox-ed mouse, in which the floxed modifications can 
be activated by local transduction of cells with lentiviruses encod-
ing Cre recombinase under control of ubiquitous or cell-type specific 
promoters, or by crossing with transgenic mice expressing Cre under 
control of neural- or glial-cell type-specific promoters (e.g., nestin 
or GFAP promoter). In these cases modifications occur early during 
embryonal development, unless promoter activity is made inducible. 
These glioma models are molecularly highly defined, and can be pro-
cessed to novel murine cell lines that are amenable for allografting. c 
PDGCs or PDX can be generated by preparing cell cultures of surgi-
cally obtained glioma material (nowadays mostly spheroid cultures) 
that can be implanted heterotopically (generally subcutaneously in 
the flank) or orthotopically (in the brain) of immunocompromised 
animals; alternatively, surgically obtained human glioma tissue can be 
directly implanted; ideally, an orthotopic xenograft of a diffuse high 
grade glioma/glioblastoma in the murine brain recapitulates not only 
the genotype, but also the phenotype of this tumor with e.g., florid 
microvascular proliferation (lower right image) and diffuse infiltrative 
growth in the white matter (upper right image). Of note, as illustrated 
by a xenograft derived from U87 cells, not all orthotopic glioma mod-
els show diffuse infiltration in brain parenchyma, and such models 
are less relevant for the study of glioma in the context of tumor-brain 
microenvironment interactions
◂
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of ENU-induced gliomas was impossible, current imaging 
techniques allow for therapy studies during which animals 
are longitudinally monitored. Obviously, testing of tar-
geted drugs in this model requires that these are equipotent 
against the human and murine targets.
Transgenic mouse models
The knowledge of the driver mutations that are involved in 
gliomagenesis has resulted in innovative genetically engi-
neered mouse models (GEMMs) of glioma (for systematic 
review of GEMMs, see [59]). An elegant approach made 
use of transgenic animals with GFAP-promoter-driven 
expression of tv-a, resulting in astrocyte specific expression 
of this retrovirus receptor. This makes these cells suscep-
tible to infection with avian leukosis virus-derived RCAS 
vectors that carry expression cassettes for e.g., auto-active 
EGFR variants [63]. Infection with such viruses will result 
in astrocytic EGFR hyperactivity. To allow for astrocytic 
infection, RCAS-vector producing chicken fibroblasts need 
to be intracerebrally injected, resulting in infection of cells 
neigbouring the needle track.
Another example in this category is the model created 
by transcranially injecting lentiviruses expressing Cre-
recombinase under control of the glial cell-specific GFAP 
promoter or the ubiquitously active CMV promoter, in 
LoxP-transgenic mice, conditionally lacking p53 or pten, 
and p16INK4a, and overexpressing the constitutively active 
KRASV12 mutant (Fig. 2b). In this model high-grade glio-
mas develop within weeks after Cre-administration that 
resemble human glioma with respect to phenotype and 
BBB [38]. In a recent publication Bardella et al. described 
a transgenic conditional mouse model in which mice carry-
ing a floxed Idh1 minigene, followed by an Idh1R132H allele 
were crossed with mice carrying a tamoxifen-inducible 
Pnestin-Cre transgene [7]. Upon administering tamoxifen to 
the offspring mice, Cre is selectively expressed in nestin-
positive neural progenitor cells in the subventricular zone 
(see also “Human glioma cell lines: neurosphere cultures”), 
resulting in deletion of the minigene and activation of the 
Idh1R132H allele in this alleged stem cell population. The 
resulting cells were more proliferative and displayed inva-
sive behavior, suggestive of an early gliomagenesis phe-
notype. Such models may well be further developed into 
lower grade diffuse glioma models.
GEMMs are very suitable to investigate behavior of 
genetically defined gliomas in an immune competent set-
ting and allow for studies on drug distribution to glioma 
cells in the brain, taking potential BBB restrictions into 
consideration [88, 89]. These models however lack the 
intratumor heterogeneity that is observed in human glio-
mas. Furthermore, in these models targeted drugs that are 
tested ideally must have similar activity against human and 
murine targets in order to predict therapeutic outcome in 
patients.
Murine glioma cell lines and allograft models
The unpredictable character of glioma formation in ENU-
induced models has stimulated researchers to create stable 
in vitro cell line cultures from ENU-induced rat gliomas, 
among which C6, 9L, T9, RG2, F98 and BT4C and RT-2 
(molecular characteristics reviewed in detail in [8]), but 
also from transgenic mice [132]. The GL261 mouse cell 
line was generated by intracranial injection of the alkylat-
ing agent 3-methylcholantrene into C57BL/6 mice [5, 140]. 
These murine glioma cell lines have the advantage that they 
can be implanted orthotopically in syngeneic, immunocom-
petent animals [8] allowing for the study of tumor immuno-
logical aspects. An exception is the C6 glioma model that 
was generated from an ENU-induced glioma in an outbred 
strain of Wistar rats. As a consequence, inoculation of C6 
cells in common Wistar rat strains results in an allogenic 
immune response and lack of tumor growth [10]. How-
ever, the cell lines that do grow in their syngenic hosts after 
intracerebral transplantation, develop into invasive cancers 
that have been used to investigate effects of targeted ther-
apy and radiotherapy [28].
Novel immunotherapy concepts have been introduced 
in cancer treatment, such as dendritic cell vaccination and 
immune checkpoint inhibition (reviewed in [146]). Gliomas 
are considered by some to be good candidates for dendritic 
cell (DC) vaccination [85], but the efficacy of this and of 
other immunotherapeutic approaches is currently hampered 
by the immune suppressive milieu in (patients with) glioma 
[51, 54]. Glioma allografts in immunocompetent animals 
are highly valuable models to optimize immune-modula-
tory therapies and improve immunotherapeutic protocols 
[166]. Yet, as indicated above, one has to bear in mind that 
the intratumoral heterogeneity of human gliomas is prob-
ably not fully recapitulated in animal models. Another 
drawback of these murine glioma models in the context of 
immunotherapy is that humanized antibodies for clinical 
use are immunogenic in such models, precluding repeated 
administration. This problem can partly be circumvented 
by using immune deficient animals (rats or mice), obvi-
ously not an adequate solution for studies in the field of 
immune therapy. Alternatively, immune-humanized mice 
may be used in which the mouse Ig-locus is exchanged for 
the human Ig-locus [13, 97, 167]. Clearly, in such models 
the targeting antibody should be reactive against the glioma 
target of interest. Genetic engineering of rat glioma cell 
lines aiming for expression of the human antigen of inter-
est may be helpful in this respect. An example of this latter 
approach is the evaluation of therapeutic efficacy of anti-
EGFRvIII antibodies using allografts of F98 rat glioma 
269Acta Neuropathol (2017) 133:263–282 
1 3
cells overexpressing human EGFRvIII [165]. So far, spon-
taneous IDH1 mutations have not been reported in murine 
glioma cell lines, making these models less relevant for the 
study of IDH mutant human gliomas. Attempts to gener-
ate stable cell cultures from transgenic mice, expressing 
IDH1R132H in nestin-positive neural progenitor cells have 
so far also failed [7].
Models of human glioma
Human glioma cell lines: conventional cell cultures
In an attempt to work with glioma models that resemble 
as closely as possible the genetic make-up of their human 
counterparts, many research groups exploit patient-derived 
glioma cell lines. The two most widely studied cell lines, 
U87 and U251, were generated in the sixties of the last 
century from patients with a glioblastoma [114, 160]. In 
the past 4 decades experiments with these lines have been 
reported in over 2000 and 1000 publications, respectively. 
The U87 genome has recently been fully sequenced [31], 
and this effort revealed an enormous number of indels, 
copy number variations and translocations, most of which 
were probably acquired during decades of cell culture. 
Indeed, only recently the consequences of cell culture with 
fetal bovine serum for genetic instability have been recog-
nized [2, 46, 67, 144]. Still, genetic aberrations from the 
original tumors that are retained in these cell lines allow 
for the detailed study of their contribution to oncogenic 
cell signaling pathways in a controlled and reproducible 
fashion. Furthermore, such cell lines also allow for rapid 
and reproducible testing of targeted drugs in vitro, as a pre-
screen for further testing in appropriate preclinical in vivo 
models.
Of note, U87 cells have found their way to many labs in 
the world, and it may be expected that, due to genetic drift 
under serum culture conditions, there is a large number of 
subclones of U87 available that may affect experimental 
reproducibility. The need for regular cell line authentica-
tion is now widely recognized and cell line authentication 
is already required by a number of scientific journals [48].
Human glioma cell lines: neurosphere cultures
The genetic drift that is caused by culturing cells under 
serum conditions has resulted in a search for alternatives. 
In 1992, Weis and Reynolds reported that neural stem cells 
(NSC) can be stably maintained and propagated as neu-
rospheres when cultured in growth-factor defined media 
in the absence of serum [121]. A subset of surgically 
obtained gliomas can be processed to genetically stable cell 
lines by growing tumor spheroids in a similar specialized 
medium containing basic fibroblast growth factor (bFGF), 
epidermal growth factor (EGF) and neuronal viability sup-
plement B27 [6, 16, 34]. Success rates of generating neuro-
sphere cultures from gliomas is however largely dependent 
on tumor grade and IDH status. Especially generation of 
cell cultures from IDH-mutated lower grade (WHO grade 
II and III) gliomas is difficult, with only few examples 
reported in the literature [76, 92, 124]. Furthermore, con-
sidering the heterogeneous composition of human gliomas, 
it is quite likely that each patient-derived glioma spheroid 
line represents only a subset of the most aggressive cells 
from the original tumor.
This directly leads to the questions how the initiating 
glioma cells diverge into the heterogeneous population of 
progeny cells and what exactly are the initiating cells. This 
issue is still not resolved. Current ideas are that many glio-
mas originate from neural progenitor cells in e.g., the sub-
ventricular zone that during normal development differenti-
ate into neuronal and glial cells. Based on the concepts of 
stem cells in healthy tissues, these glioma stem-like cells 
(GSLCs), also called glioma-initiating cells (GICs), are 
believed to divide asymmetrically, yielding a novel stem-
like cell that is resistant to chemotherapy and radiotherapy 
and is responsible for tumor progression, and a non-stem-
like daughter cell [136]. This hypothesis would qualify 
GSLCs as the cells that are most essential, but also most 
difficult to eradicate in glioma therapies.
Interestingly, glioma spheroid cultures contain char-
acteristics of GSLCs, and may express stem cell markers 
such as CD133, Nestin, Sox2 and SSEA-1 [131]. However, 
expression of these markers varies widely, making it dif-
ficult to unequivocally define the initiating cells in gliomas. 
Furthermore, lack of expression of GSLC markers does 
not necessarily imply lack of the ability to generate tumors 
[64]. Even though in vitro and in vivo glioma models are 
promising tools for further elucidation of the molecular and 
functional characteristics of GSLCs/GICs (including iden-
tification of the best markers for recognizing these cells) 
[157], so far this has not led to broad consensus on what 
exactly GSLCs/GICs are and what their impact is in the 
pathobiology of gliomas.
When bFGF and EGF in the cell culture medium are 
replaced with serum, cells rapidly lose intercellular con-
nections within the neurospheres and undergo marked 
phenotypical changes: cells start to adhere to plastic, flat-
ten, acquire a more fibroblast appearance, and loose GSLC 
markers [82, 110]. When testing the effects of different cul-
ture conditions using the E98-model (derived from a human 
glioblastoma [30]) in our lab, upon intracerebral implanta-
tion only E98 cells cultured as neurospheres retained the 
capacity to diffusely infiltrate into the brain parenchyma, 
whereas E98 cells grown under serum conditions had lost 
this capacity (Fig. 3). Similar observations were made 
by others [82]. The exact mechanism underlying this 
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phenomenon is unclear, but may have to do with a GSLC 
population with invasive potential that is enriched in tumor 
spheroids [135, 139].
Nowadays, glioma cultures can be relatively easily mod-
ified with CRISPR/Cas9 technology, allowing for the eluci-
dation of the role of individual oncogenes and tumor sup-
pressor genes. Furthermore, it is now common practice to 
generate luciferase-expressing glioma cells, enabling longi-
tudinal non-invasive follow up of tumor development in the 
mouse brain [12, 21].
Heterotopic versus orthotopic grafts of glioma cell lines
Subcutaneous xenografting of human glioma cells in 
immunocompromised mice is a frequently used approach 
to obtain preclinical proof of concept for the efficacy of 
targeted drugs [123]. Glioma xenografts grown in the sub-
cutaneous space have the advantage that tumor develop-
ment can be followed visually and quantified in terms of 
tumor dimensions, allowing rapid testing of treatment effi-
cacy. Such experiments may yield valuable results, espe-
cially if the drugs directly act on tumor cells (e.g., inhibi-
tors of hyperactive oncogenes). Caution is however in 
place when drug activity is based on disturbing the inter-
action with the tumor microenvironment, such as in case 
of anti-angiogenic drugs or particular metabolic inhibitors. 
Subcutaneous glioma models lack the appropriate CNS 
microenvironment that has an essential role in glioma biol-
ogy. Studies with such subcutaneous models may result 
in overinterpretation of effects of angiogenesis inhibitors 
[155] (see “Angiogenesis inhibition in preclinical glioma 
models”).
Orthotopic patient‑derived xenografts
The desire to circumvent culture-related problems as 
described above combined with the increased understand-
ing that glioma biology and therapy are heavily influenced 
by interactions between cancer cells and their microenvi-
ronment have increased the interest in the use of orthotopic 
glioma xenografts. Freshly obtained surgical glioma sam-
ples can be directly injected into the brains of immune-
deficient mice using stereotactic devices or by a free-
hand procedure and maintained by serial transplantation 
[30, 76, 92]. Using such an approach we have created the 
IDH1R132H-E478 xenograft model that is genetically highly 
similar to the anaplastic oligodendroglioma from which it 
was derived [102]. RNAseq analyses of such models allows 
the discrimination of human and mouse transcripts, pre-
venting contaminating contributions of host non-neoplastic 
cell transcripts (which is an unavoidable flaw of studies on 
clinical cancer specimens).
A drawback of such glioma models is that xenografting 
is performed in immune-deficient animals and there will be 
a selection for the fastest growing cell clones resulting in 
reduced intratumor heterogeneity. Furthermore, orthotopic 
implantation of cell lines is not a guarantee for a clinically 
relevant phenotype: whereas orthotopic U251 xenografts 
have a striking phenotypic resemblance to human GBM 
[96], including diffuse infiltration in the brain parenchyma 
and palisading necrosis, U87 cells generally develop to 
bulky, sharply demarcated lesions that lack such infiltrative 
growth [29, 69] (see also Fig. 2).
In light of the highly promising results that are obtained 
with immune checkpoint inhibitors for other cancer types, 
Fig. 3  Cell culture conditions impact the phenotype of orthotopic 
E98 glioma xenografts. E98 glioma cells grown as adherent cells in 
serum-supplemented culture medium lose the capacity to grow dif-
fusely in the brain (left panel). Glioma cells are visualized via immu-
nohistochemical staining for c-MET. Note the sharp demarcation 
between tumor (growing in the leptomeninges here) and brain paren-
chyma in the left panel, whereas E98 tumor cells diffusely infiltrate in 
the brain parenchyma after passaging as neurospheres (right panel). 
Of note, photographs are representative examples from experiments 
in which E98 cells, grown as adherent cultures or spheroid cultures, 
were injected in groups of 5 mice using exactly the same injection 
procedure. Bars indicate 200 µm
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reconstituting a human immune system in xenografted 
mice will be of high importance to test these therapies for 
glioma in a preclinical setting [97, 167]. Whether patient-
derived xenograft (PDX) models can be optimized by using 
humanized mice to allow for testing of clinically available 
immune checkpoint inhibitors, remains to be seen.
Other glioma models
The vast majority of glioma models reported in the litera-
ture concerns models for diffuse gliomas, but preclinical 
models for non-diffuse gliomas such as pilocytic astrocy-
tomas and ependymomas have been reported as well (in 
vitro, heterotopic or orthotopic murine models, GEMMs) 
[55, 72, 95, 115]. Obviously, like for diffuse gliomas, in 
an ideal situation the preclinical models for such gliomas 
are reproducible and closely resemble their human counter-
parts with regard to genetic background, intratumoral het-
erogeneity and tumor microenvironment.
As generation of mouse and rat models of glioma can 
be a slow process, in vivo detection of orthotopic gliomas 
requires sophisticated equipment, and drug screenings in 
these models are time-consuming and costly endeavours, 
some more ‘exotic’ glioma models have been developed. 
A potentially interesting example is the zebrafish (Danio 
rerio) model for the study of gliomas [154, 158]. Zebrafish 
embryos are increasingly used for cancer studies since 
the discovery that pathways of tumorigenesis are simi-
lar in humans and zebrafish [66]. In a typical experiment 
hundreds of day 3 post-fertilization zebrafish embryos are 
injected with tumor cells, stained with a fluorescent mem-
brane dye. Using the pigmentation-mutated casper strain of 
zebrafish that remain transparent during life, cancer cells 
can be readily visualized using UV microscopy. Intracer-
ebral implantation of human glioma cells in zebrafish was 
shown to result in xenografts with phenotypes that were 
similar to xenografts in mouse, grown from the same cells 
[45]. The zebrafish system allows semi-high-throughput 
drug screening, e.g., by adding compounds in the water 
[158]. A potentially serious drawback of the zebrafish sys-
tem is that glioma cells need to adapt to function at 32 °C, 
with possible consequences for metabolism and activity of 
oncogenic pathways. Furthermore, one needs to take into 
account that in zebrafish the BBB starts to develop from 
day 3 post fertilization and is fully developed only at day 
15 post fertilization, and that the immune system has not 
matured in the early stages of development as well [80, 
162]. Furthermore, it is not yet clear whether the zebrafish 
accommodates growth of all sorts of glioma cells, includ-
ing the difficult-to-grow IDH mutant gliomas.
Another model of interest is the fruit fly (Drosophila 
melanogaster), a highly versatile genetic model system in 
which specific gene functions can be manipulated in a sin-
gle-cell fashion in an in vivo setting [161]. This provides 
the opportunity to investigate the effect of genetic aberra-
tions in an intact nervous system. Many molecular path-
ways, such as the RTK signaling pathways, are highly con-
served between invertebrates and humans [120]. It has been 
reported that these models may recapitulate key character-
istics of glioblastoma with regard to increased proliferation 
and migration [117].
The downsides of available experimental animal models 
of glioma has raised interest in using dogs with naturally 
occurring gliomas for testing of novel drugs and optimizing 
novel treatment concepts [81]. Although canine gliomas 
probably represent a good intermediate between murine 
models and humans, being more relevant in terms of intra-
tumoral heterogeneity and immune system, low incidence 
and lack of canine-specific molecular testing facilities, 
hamper larger studies.
A recent development has been that human fibroblasts 
after p53 knock down are converted to inducible pluripo-
tent stem cells (iPSCs) that can subsequently be differen-
tiated to neural progenitor cells to yield TP53-mutated 
NPCs. These cells can be transformed to glioma initiating 
cells by lentiviral transduction of oncogenes [128].
Glioma models and predictive medicine; a reality 
check
The exact glioma model used is an important determi-
nant for the outcome of preclinical therapeutic studies. 
After briefly underscoring the importance of the molecular 
underpinnings and of the microenvironment of the model, 
anti-angiogenic therapy and tumor-cell metabolism will 
be discussed in more detail as examples where exploita-
tion of inappropriate models may easily lead to deceptive 
information.
The importance of molecular underpinnings 
and microenvironment
Lots of (combinations of) mutations that are common in 
human glioma, are retained in human glioma cell lines. In 
vitro studies using appropriate cell lines are therefore well 
suited to investigate interactions between aberrant path-
ways and establish optimal concentrations of inhibitors, e.g. 
to achieve potential synthetic lethality [75]. A large propor-
tion of gliomas have a dysfunctional CDKN2A, the gene 
encoding the cyclin D1 inhibitor p16INK4A. These cells have 
a defective G1-S checkpoint that can however be corrected 
pharmacologically by palbociclib. This CDK4/6 inhibitor 
has recently been approved by the FDA and the European 
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Medicine Agency (EMA) for treatment of women with 
advanced breast cancer [47]. Treatment of patient-derived 
p16INK4a−/−glioma cell lines, grown as adherent cells or as 
spheroids, with palbociclib results in an effective block of 
cell cycle progression already at µmolar concentrations as 
shown by incorporation of nucleotide analogues bromo-
deoxyuridine (BrdU) and 5-ethynyl-2′-deoxyuridine (EdU) 
(Fig. 4, unpublished work). These results confirm litera-
ture data that a large percentage of patient-derived glioma 
explants respond to palbociclib [23]. However, its clinical 
usability is strongly restricted because palbociclib is a sub-
strate for P-glycoprotein (a family of ATP-dependent trans-
porter proteins in the BBB that pump out the recognized 
substrate), reducing drug distribution behind the BBB [36]. 
Once the BBB limitations are overcome (see below) palbo-
ciclib may indeed be used to improve prognosis for a large 
proportion of glioma patients.
Hyperactivity of the phosphoinositol-3-phosphate 
(PI3 K) pathway in glioblastoma is common, due to (a 
combination of) amplified or otherwise mutationally acti-
vated oncogenic RTKs, and/or loss of the phosphatase 
PTEN [27, 35]. Aberrant expression of epidermal growth 
factor receptor (EGFR) and/or the ligand-independent 
EGFR mutant EGFRvIII (a product of a genetic deletion 
resulting in loss of exons 2-7 in the mRNA) is a frequent 
phenomenon in glioblastoma [26, 60], driving growth and 
migration of tumor cells [141]. Alterations in other RTKs 
that are frequently encountered in glioblastoma are muta-
tions in PDGFRα and MET [103]. Also these mutations 
are retained in cell lines. We previously showed that tar-
geted inhibition of MET by cabozantinib is highly effec-
tive in E98 cells in vitro, blocking MET phosphorylation 
and cell proliferation with IC50 in the nmolar range. Test-
ing the same drugs in orthotopic xenografts generated from 
the same cell line resulted in increased survival of mice, yet 
did not prevent development of treatment resistant cancers 
[100]. Such differences in effects of the same drug on the 
same cell line in vitro and in vivo illustrates the important 
role of the tumor microenvironment.
The BBB is designed to protect neural tissue from toxic 
substances in the blood. In large areas of diffuse infiltra-
tive glioma this barrier also shields cancer cells from drugs. 
The BBB is composed of a relatively impermeable layer 
of endothelial cells that communicate with astrocytes via 
Fig. 4  Example of promising in vitro effect of CDKN2A-mutation 
targeting that is difficult to translate into clinical efficacy. Two differ-
ent patient-derived glioblastoma models (E98 adherent cells, N13-16 
spheroid cultures, both characterized by dysfunctional CDKN2A), 
were incubated with placebo (left panels) or with the CDK4/6 
inhibitor palbociclib (right panels). Visualization of DNA synthesis 
(S-phase of the cell cycle) with BrdU or EdU (as indicated) shows 
that palbociclib effectively prevents entry into the S-phase. Although 
such in vitro results are very promising, also because 80% of human 
glioblastomas have dysfunctional CDKN2A leading to a defective 
G1-arrest, in vivo diffuse gliomas may well be protected from palbo-
ciclib because this drug is substrate for p-glycoproteins of the BBB 
[36]
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contacts with astrocytic end feet [9, 79]. Except for creat-
ing a physical barrier, endothelial cells of the BBB express 
a large diversity of P-glycoprotein family members, mak-
ing the BBB impermeable to the vast majority of drugs 
[15, 39, 87, 89, 149]. Therefore it is of high importance 
that drugs that have been positively tested on cell lines are 
subsequently tested in appropriate preclinical models that 
have retained diffuse growth, and in which cancer cells 
may ‘hide’ behind the BBB. For drugs that cannot pass the 
BBB, there is the need to find solutions for local and con-
trolled BBB disruption, or to discover novel targeted drugs 
that are not substrate for the P-glycoprotein family of drug 
transporters [87, 89, 149]. Numerous research efforts to get 
drugs over the BBB are ongoing, including active transport 
of peptide- or antibody-coated nanoparticles [50, 73, 145]. 
Mechanical temporary and spatially restricted disruption 
of the BBB with high intensity focused ultrasound (HIFU) 
[32, 61, 77] or via stereotactic radiotherapy [4] is an alter-
native approach that may carry promise for the future but 
needs more preclinical validation.
One of the recent breakthroughs in oncology has been 
the implementation of immune checkpoint inhibitors, com-
prising antibodies against programmed death-1 (PD-1, 
nivolumab) or cytotoxic T-lymphocyte antigen-4 (CTLA-4, 
ipilimumab) on cytotoxic T-lymphocytes. These antibodies 
prevent the immune-suppressive interactions between can-
cer cells and cytotoxic T-cells, boosting anti-tumor immu-
nity [152] and have now been FDA- and EMA-approved 
or are in clinical trial for a large number of tumor types. 
With currently available glioma models, preclinical testing 
of such highly promising approaches is an enormous chal-
lenge. PDXs are unfit for this purpose, given the immuno-
compromised status of the recipient mice, and humanized 
mice are probably required for preclinical testing of these 
concepts. Syngeneic models would require that murine 
antibodies against the murine equivalents of PD-1 and 
CTLA-4 are generated, assuming that these immune check-
point systems work alike in humans and rats or mice. Pos-
sibly, ENU-induced gliomas would recapitulate human 
gliomas best with respect to genetic heterogeneity and 
immunocompetence, but as discussed above this model 
lacks reproducibility.
Angiogenesis inhibition in preclinical glioma models
Whereas most targeted therapies in oncology focus on 
aberrations in tumor cells, anti-angiogenic treatment using 
bevacizumab, one of the very few FDA-approved new 
therapies for glioblastoma in the USA, is targeting the 
interactions between tumor cells and the tumor microen-
vironment. Based on the VEGF-induced florid MVP that 
is characteristic for glioblastoma, this cancer type has his-
torically been looked at as angiogenesis-dependent, hence 
amenable for targeting with VEGF-pathway inhibitors. 
Obviously, in vitro glioma cell cultures are not suitable to 
investigate this concept. Lots of studies have concentrated 
on patient-derived glioma cell lines that were grown as sub-
cutaneous xenografts in immune-deficient mice [11, 86]. 
These studies generally yielded highly promising results, 
with tumor stabilization or even regression, whether with 
anti-VEGF antibodies or with small compound VEGF RTK 
inhibitors. Combined data from such studies and radiologi-
cal responses in phase II clinical studies for recurrent glio-
blastoma resulted in accelerated FDA-approval for beva-
cizumab as first line treatment for recurrent glioblastoma 
in 2009 [99]. Unfortunately, large phase III trials testing 
bevacizumab for newly diagnosed glioblastoma showed no 
positive effect on overall survival, often despite an initial 
radiological response [25, 52].
It is now broadly accepted that the FDA approval of 
anti-VEGF-A treatment for recurrent glioblastoma in 2009 
was at least partly based on cases showing a radiological 
pseudoresponse (resulting from ‘normalization’ of acti-
vated tumor blood vessels) rather than from a tumoricidal 
response [14, 70, 151, 152]. Of note, this phenomenon was 
demonstrated before in different animal models. For exam-
ple, VEGF-expressing melanoma metastases in the murine 
brain that were readily visible in contrast-enhanced MRI 
became invisible upon treatment with the VEGFR2 inhibi-
tor vandetanib, even while they progressed by growing in 
the space of Virchow-Robin via vessel co-option [84]. Sim-
ilarly, several studies using orthotopic models of diffuse 
glioma had shown that these tumors can grow in CNS tis-
sue independent of angiogenesis, especially cells that over-
express EGFR or MET [103, 141]. Accordingly, anti-angi-
ogenic treatment does not prevent growth of these cancers 
[101] but it can increase hypoxia and glycolysis in angio-
genic parts of glioma [58]. In this situation treatment with 
angiogenesis inhibitors diminishes contrast-enhancement 
in MRI scans without preventing diffuse infiltration in the 
brain parenchyma [100, 101], copying the phenomena seen 
in the clinic. Meanwhile, reduction of hyperpermeability of 
brain tumor microvessels by anti-VEGF-A treatment may 
have a rapid positive effect on edematous brain swelling, 
thereby temporarily improving the quality of life [37, 70].
It is important to consider the cellular principles under-
lying the different responses of subcutaneous and intracer-
ebral tumors to anti-angiogenic treatment. Tumor growth in 
the originally avascular, subcutaneous space requires that 
tumor cells can initiate transcriptional programs that rescue 
them from starvation [62]. Normally this rescue is accom-
plished by switching on hypoxia-induced transcriptional 
programs in cells that are located beyond ~ 100–200 µm 
from the most nearby blood vessel (the maximum range of 
oxygen diffusion), including expression of the chemotactic 
factor VEGF-A, leading to blood vessel growth towards the 
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tumor [125]. The situation in brain, one of the most vascu-
larized organs in the body, is entirely different. Here, dif-
fuse infiltrative glioma cells can incorporate the abundantly 
present, pre-existent brain microvessels (among others 
via vessel co-option) [40, 83] (Fig. 5). Of note, orthotopic 
implantation of glioma cells may not necessarily lead to an 
adequate phenotype for diffuse glioma. For instance, ortho-
topic implantation of U87 cells generally results in bulky, 
well-demarcated tumors with a disrupted BBB, lacking 
diffuse infiltrative growth along white matter tracts [49]. 
Anti-angiogenic studies using subcutaneous or ‘bulky’ 
orthotopic glioma models thus carry the risk of overinter-
pretation of the therapeutic results, even more so if these 
studies use drugs that do not pass the BBB.
Metabolic considerations
Another important reason to study glioma in the orthotopic 
setting relates to tumor cell metabolism [42]. In the brain, 
ubiquitous amounts of glutamine and the neurotransmitter 
glutamate are present as part of the glutamine-glutamate 
cycle (Fig. 6). Together with glucose, glutamine and/or 
glutamate may be important carbon and nitrogen donors 
for glioma cells [3], especially those with IDH mutations. 
The biology of IDH mutations has been extensively studied 
and is covered in excellent reviews e.g. [1, 18]. Whereas 
wild type IDHs produce α-KG and NADPH from isoci-
trate and NADP+, IDH mutants (mostly hotspot mutations 
IDH1R132X or IDH2R140X/IDH2R172X) consume α-KG and 
NADPH while producing the oncometabolite 2-hydroxy-
glutarate (D-2-HG) [163]. This has two important implica-
tions. Firstly, since α-KG and NADPH take important roles 
in fundamental processes such as fatty acid synthesis and 
maintenance of redox potential, expression of mutated IDH 
results in metabolic stress [147, 148]. Secondly, D-2-HG is 
an inhibitor of a large group of α-KG-dependent enzymes 
that are involved in epigenetic regulation and induces 
G-CIMP (see also “Molecular pathology of gliomas”) [43].
We previously suggested that one of the reasons for the 
unique phenotype of diffuse growth of IDH-mutated glio-
mas relates to the metabolic stress, translating into addic-
tion to glutamate as an alternative carbon source, making 
this neurotransmitter to a potential chemotactic factor [148] 
(Fig. 6). Because not all culture media routinely contain 
this non-essential amino acid, glutamate dependence would 
be incompatible with standard in vitro growth condi-
tions and could partly explain the difficulty with produc-
ing stable glioma cell cultures carrying endogenous IDH 
mutations [113]. Only in the last years a number of IDH-
mutated glioma models have become available, mostly as 
patient-derived orthotopic xenografts [76, 92, 102, 124].
The high incidence of IDH-driver mutations in gliomas, 
combined with the lack of appropriate in vitro cell cultures 
has resulted in numerous studies in which effects of IDH-
mutants are tested in cell models utilizing overexpression 
of mutated IDH. Whereas such models have proven valu-
able to investigate epigenetic phenomena and metabolic 
fluxes, they may also result in misinterpretation, depending 
Legend
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Pre-existent vessel
Sprouting endothelial
cell
ba
Tumor growth via 
co-option of 
pre-existent 
vasculature
Angiogenesis
Fig. 5  Schematic overview of tumor growth via angiogenesis versus 
vessel co-option. a Schematic representation of the dogma of angi-
ogenesis-dependent growth of a tumor. When a tumor outgrows the 
capacity of the vasculature, hypoxic stress (indicated by blue cells) 
initiates sprouting angiogenesis as a rescue pathway (here presented 
as yellow vessels. b Especially in tissue with rich pre-existent vas-
culature (such as brain tissue), tumors may grow through vessel co-
option in an angiogenesis-independent fashion
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on the specific cell system and desired read-out. For exam-
ple, IDH-wild-type glioma cells routinely express the 
enzyme branched-chain amino acid transferase-1 (BCAT1) 
that converts α-KG to glutamate [143]. Together with the 
antiporter System Xc-, BCAT1 is responsible for maintain-
ing redox potential. Glutamate is secreted from the cell via 
this transporter in exchange for cystine that entails reduc-
tive power [122]. In gliomas carrying the endogenous IDH 
mutation, BCAT1 is silenced via promoter hypermethyla-
tion [94, 143]. Consequently, glutaminolysis in these can-
cers is a one-way reaction from glutamine/glutamate to 
α-KG. Introduction of a mutated IDH gene in a cell with 
wild-type IDH background will thus result in a competition 
between BCAT-1 and mutated IDH1 for α-KG, a situation 
that does not reflect the endogenous situation. Whether full 
penetrance of D-2-HG-induced epigenetic effects in engi-
neered cell lines can be achieved to the extent that the met-
abolic phenotype of clinical IDH-mutated glioma is fully 
mimicked, is an open question. Experience so far is that 
IDHmut introduction in cells results in a gradual loss of the 
mutated protein, suggestive of a selection against mutant-
expression, resulting in selective overgrowth of cells with 
no or low expression levels of the mutated protein [6, 113]. 
Introduction of mutant IDH disrupts metabolic balances 
that may result in model-specific artefacts.
Summarizing remarks
Glioma models that have been developed so far have 
greatly enhanced our understanding of glioma forma-
tion and metabolism and have contributed to the develop-
ment and implementation of novel treatment strategies. 
As a recent example, partly based on in vitro studies and 
in vivo observations in mice and rabbits, in 2015 the FDA 
approved Tumor Treating Fields (TTF) as a therapeutic 
Glutamate (Glu)
Presynaptic 
neuron
Postsynaptic 
neuron
Glutamate
receptor
Gln
Glu
glutaminase
Glu
Glu
α-KG
Gln
Gln
Gln
glutamine
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IDH1MUT
Legend
Astrocyte
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Ca2+ Ca2+
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Fig. 6  Schematic representation of the glutamine-glutamate cycle 
in the brain. In the brain, glutamate (Glu) is released by presynap-
tic neurons to the synaptic cleft. Glutamate activates glutaminergic 
receptors that undergo a conformational change to allow influx of 
extracellular calcium. This triggers membrane depolarization in the 
postsynaptic neuron and induces signal transduction. The excess of 
glutamate in the synaptic cleft has to be removed to prevent excito-
toxicity. Astrocytes take up surplus glutamate through various gluta-
mate importers and convert it to glutamine (Gln) through glutamine 
synthetase. Glutamine is exported to the capillaries (not shown), or is 
transferred back to the neurons. Subsequently, neurons can then con-
vert back the glutamine to glutamate, closing the glutamine-glutamate 
cycle. Glutamate can be imported by IDHmut glioma cells in order to 
supply cells with αKG as a rescue pathway
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modality for patients with newly-diagnosed glioblastoma 
(http://www.fda.gov/NewsEvents/Newsroom/PressAn-
nouncements/ ucm465744.htm) [65].
Optimal exploitation of glioma models remains chal-
lenging though. Clearly, diffuse glioma remains a difficult 
tumor to treat, not in the least because of its diffuse infiltra-
tive growth and the substantial inter- and intratumoral het-
erogeneity [118]. Up until now, creating adequate models 
for IDH mutant gliomas proves to be very difficult. Also, 
intratumoral heterogeneity of diffuse gliomas cannot be 
recapitulated to the fullest in in vitro or in vivo models. 
For several therapies the BBB (which is relatively intact in 
large parts of diffuse glioma) is a true barrier, and modeling 
this barrier is a difficult task in itself. Yet another challenge 
lies in the development of appropriate models that can be 
used to test immunotherapy; in vitro studies using cell 
lines and xenograft models in immunodeficient animals 
are inherently unfit for this purpose. So far, a preclinical 
model that perfectly recapitulates (one or another subtype 
of) human glioma does not exist. Still, the models that are 
available may be very useful, but it is of paramount impor-
tance to carefully select the most appropriate glioma model 
for a particular research question, meanwhile realizing not 
only the strengths but also the weaknesses of the model 
used.
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